Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 5Recruiting 4Active not recruiting 3Terminated 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 14Tumor-Agnostic 4Genitourinary 4Breast 3Sarcoma 2Head & Neck 2Gastrointestinal 2CNS 2Thoracic 1Other solid neoplasm 1

Conditions

Neoplasms 2Neoplasm Metastasis 2

Interventions

pembrolizumab 25Specimen Handling 17Blood Specimen Collection 17Biopsy 16Magnetic Resonance Spectroscopy 15atezolizumab 11Surveys and Questionnaires 11Radiosurgery 9Bevacizumab 9Radiotherapy 8Nivolumab 8Fluorouracil 8Standard of Care 7Paclitaxel 7Irinotecan 7Gemcitabine 7Cisplatin 7olaparib 6durvalumab 6Palliative Care 6Oxaliplatin 6Leucovorin 6Cyclophosphamide 6Carboplatin 6Capecitabine 6alectinib 5abemaciclib 5Trastuzumab 5Interviews as Topic 5Exercise 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × niraparib × Tumor-Agnostic × Clear all
NCT05694715 2026-03-17

Combination Therapy in Cancers With Mutations in DNA Repair Genes

University of California, San Francisco

Phase 1 Recruiting
24 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04341181 2025-07-25

ProTarget

Rigshospitalet, Denmark

Phase 2 Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

Oslo University Hospital

Phase 2 Recruiting
3,000 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

The Netherlands Cancer Institute

Phase 2 Recruiting
1,550 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡